All In Biotech

Drug Trial Radar · NCT06959511

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

ZAnzalintinib Neoadjuvant EValuation in Thyroid Oncology (ZANEVO)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Jul 22, 2025

Primary completion

Mar 1, 2028

Study completion Oct 1, 2030

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Exelixis
First posted
May 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.

Conditions

  • Neoadjuvant Treatment
  • Thyroid Cancer

Interventions

  • ZanzalintinibDrug

    Given by po

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and adverse eventsTime frame: From baseline until completion of neoadjuvant therapy; an average of 6 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Cleveland Clinic Taussig Cancer Institute

    Cleveland, Ohio · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.